Ji, Marco H.
Zaidi, Moosa
Bodnar, Zachary
Wang, Sean K.
Kumm, Jochen
Moshfeghi, Darius M.
Funding for this research was provided by:
Research to Prevent Blindness
National Eye Institute (P30-EY026877, P30-EY026877, P30-EY026877, P30-EY026877)
Article History
Received: 27 May 2022
Accepted: 21 October 2022
First Online: 11 November 2022
Competing interests
: M.H.J., None; M.Z., None; Z.B, Ainsly (Consultant, Equity); S.K.W., None; J.K., Pr3vent INC (F,CEO); D.M.M, Ainsly (Consultant, equity), Alexion (Consultant), Apellis (PI), Bayer Pharma AG (SC,C), dSentz, Inc. (Founder,Equity,BOD), Genentech (grant support), Grand Legend Technology, LTD (Equity), Pr3vent INC (founder,Equity,BOD), Prime Medical Education (C), Promisight, Inc (Founder,Equity,BOD), Pykus (Equity,SAB), Regeneron (Steering Committee), SLACK, Inc (C), Vindico (C), Visunex (Equity).